Evidence map›Paper›PMID 41388037›Full record

ArticleScientific reports2025

Engineering filamentous potato virus X as a platform nanotechnology for nucleic acid gene delivery.

Bryan Duoto, Michael Tong, Krister J Barkovich, Juliane Schuphan, Prashant Mali, Nicole F Steinmetz

Abstract readEvaluation Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bryan DuotoAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093, USA.
Michael TongShu Chien-Gene Lay Department of Bioengineering, University of California, La Jolla, San Diego, CA, 92093, USA.
Krister J BarkovichCenter for Nano-ImmunoEngineering, University of California, San Diego, La Jolla, San Diego, CA, 92093, USA.
Juliane SchuphanInstitut für Molekulare Biotechnologie, RWTH Aachen University, Worringer Weg 1, 52074, Aachen, Germany.
Prashant MaliShu Chien-Gene Lay Department of Bioengineering, University of California, La Jolla, San Diego, CA, 92093, USA.
Nicole F SteinmetzAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, 9500 Gilman Dr., La Jolla, San Diego, CA, 92093, USA. nsteinmetz@ucsd.edu.

Funding

Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
NCI NIH HHS R01 CA224605NIH HHS R01 CA224605
6 · The paper itself

Abstract

Nucleic acid therapeutics and gene delivery platforms have the potential to change the way we treat disease, enabling precision medicine. Advances in biotechnology have allowed for production of virtually any functional protein or peptide in the human body through the introduction of various classes of RNA, including regulatory and coding RNAs (e.g., mRNA) in the form of linear or circular RNA (circRNA). To be effective, nucleic acid therapeutics require safe, stable, and efficient delivery vehicles that protect the otherwise labile cargo from degradation, promote cellular uptake, and facilitate payload release. Lipid nanoparticles (LNPs) have enjoyed recent clinical success for the delivery of mRNA to combat disease - especially against coronavirus 2019 (SARS CoV-2) and, more recently, against high-grade ductal breast carcinoma (clinical trial) - marking significant milestones for RNA nanomedicines. As an alternative to LNPs and mammalian viral vectors, we report the use of nucleoprotein components from a filamentous plant virus, potato virus X (PVX) as an RNA platform delivery technology. Designer nucleoprotein complexes of filamentous and halo-shaped nanoparticles were obtained through self-assembled templating on custom mRNAs and circRNAs. The flexuous nature of the PVX platform enabled the packing of circRNA yielding a unique nanoparticle platform. We explored assembly from coat protein (CP) obtained from PVX particles produced in planta but also extended the design space by producing recombinant CP by bacterial expression. Controlled mixed assemblies were achieved allowing the programming of mosaic particles with integrated functionality; length control was also demonstrated, resulting in bespoke nucleic acid delivery vehicles for tunable pharmacology. Using reporter genes, we demonstrate successful transfection of eukaryotic cells and target protein expression.

Indexed as

Capsid ProteinsGenetic VectorsGene Transfer TechniquesPotexvirusRNAAnimalsGenetic TherapyNanotechnologyCapsid ProteinsRNA

Identifiers

PMID41388037
PMCPMC12700909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.